FULC Q3 2019 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FULCFulcrum Therapeutics, Inc.

$411M

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$13M

Operating Income

-$17M

Net Income

-$17M

EPS (Diluted)

$-0.93

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$116M

Total Liabilities

$14M

Stockholders' Equity

$102M

Cash & Equivalents

$102M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$13M	$0	—
Operating Income	-$17M	-$9M	-87.1%
Net Income	-$17M	-$9M	-85.0%